Trial PHERGain_MedOPP096

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

PHERGain_MedOPP096

Full title

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer:
FDG-PET response-adapted strategy. The PHERGain study

Responsible organization

Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany

Classification	Code	Description
-		Breastcancer

Phase

Status

Recruitment finished

Votes

Institutional review board - vote

Positive

Institutional review board - vote date

2018-02-15

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy line

Therapy

Zielgerichtet - Therapieart: neoadjuvant

	Function	Prename	Surname	Organization
	Responsible contact	Johannes	Ettl	Frauenklinik Frauenklinik Ismaninger Str. 22 81675 München Germany